Aquestive Therapeutics (NASDAQ:AQST) Research Coverage Started at Raymond James

Investment analysts at Raymond James started coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a note issued to investors on Thursday, MarketBeat reports. The brokerage set an “outperform” rating and a $7.00 price target on the stock. Raymond James’ price target suggests a potential upside of 70.73% from the stock’s current price.

AQST has been the subject of several other research reports. JMP Securities lifted their price target on Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Friday, March 15th. HC Wainwright lifted their price objective on Aquestive Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Monday, March 18th.

Aquestive Therapeutics Price Performance

AQST opened at $4.10 on Thursday. The stock has a 50-day moving average price of $3.49 and a 200-day moving average price of $2.41. The firm has a market cap of $300.53 million, a PE ratio of -29.28 and a beta of 2.85. Aquestive Therapeutics has a 1 year low of $0.82 and a 1 year high of $6.23.

Insider Buying and Selling

In related news, insider Alexander Mark Schobel sold 50,000 shares of Aquestive Therapeutics stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $6.00, for a total value of $300,000.00. Following the completion of the sale, the insider now directly owns 984,476 shares in the company, valued at approximately $5,906,856. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aquestive Therapeutics

Large investors have recently made changes to their positions in the company. Legato Capital Management LLC bought a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at about $688,000. Armistice Capital LLC grew its stake in shares of Aquestive Therapeutics by 314.5% during the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 3,642,000 shares during the period. Acadian Asset Management LLC grew its stake in shares of Aquestive Therapeutics by 238.8% during the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock valued at $841,000 after purchasing an additional 388,017 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock valued at $379,000 after purchasing an additional 30,898 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at about $65,000. 32.45% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.